Premenopausal breast cancer is a biologically distinct and more aggressive disease than postmenopausal breast cancer and is the leading cause of cancer death in women 20-59 years old.1,2 ,3 Historically there younger women were treated the same as their older counterparts, researchers however have more recently begun to focus on improving the treatment outcomes for these women.
About Kisqali (ribociclib) is a precision cancer medicine selective for a cyclin-dependent kinase. This class of drugs helps slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably.
MONALEESA-7 is a Phase III clinical trial evaluating the effectiveness of Kisqali by directly comparing Kisqali in combination with oral hormonal therapies and goserelin to endocrine treatment alone in premenopausal or perimenopausal women with HR+/HER2- advanced breast cancer who had not previously received endocrine therapy for advanced disease.
More than 670 women ranging from 25-58 years in age were treated in the MONALEESA-7 trial comparing Kisqali with or without endocrine therapy. The study met its primary endpoint of progression-free survival, demonstrating that the Kisqali combination therapy was superior treatment to endocrine treatment alone in first-line treatment of premenopausal women with HR+/HER2- advanced breast cancer.
Kisqali is the first CDK4/6 inhibitor to be studied in a Phase III global trial exclusively focusing on premenopausal women with HR+/HER2- advanced breast cancer and more extensive outcome data will be presented at the forthcoming San Antonio Breast Cancer symposia in December.
2. Benz CC. Impact of aging on the biology of breast cancer. Crit Rev Oncol Hematol. 2008;66:65-74
3. World Health Organization. Women’s health fact sheet. September 2013. Available at http://www.who.int/mediacentre/factsheets/fs334/en/(link is external). Accessed October 2017.
Copyright © 2017 CancerConnect. All Rights Reserved.